Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

IBM and Swiss Hospital Test New Tool for Diagnosing Cancer

Published: Thursday, October 24, 2013
Last Updated: Thursday, October 24, 2013
Bookmark and Share
The compact and easy-to-use device may help unravel tumor heterogeneity and assist in personalized treatment strategies.

IBM scientists are collaborating with pathologists at the University Hospital Zürich to test a new proto-type tool to accurately diagnose different types of cancer. This work is based on a technology developed by IBM scientists called a microfluidic probe, which slightly resembles the nib of a fountain pen.

A critical step in the diagnosis of cancer is the analysis of a patient's biopsy tissue sample, which sometimes can be as small as a pinhead. Even with such a small sample, pathologists can test for the absence or presence of tumor cells and provide important information pertaining to the course of treatment to doctors.

To analyze samples, pathologists typically stain the tissue sample with liquid reagents. The intensity and distribution of the color stain classify and determine the extent of the disease. While this approach provides insights into the tumor, it is increasingly being realized that significant variations exist within the tumor itself; mapping these variations may help understand the drivers for each tumor, and consequently assist in personalizing treatment strategies.

Based on decades of experience in designing silicon computer chips, IBM scientists have developed an innovative technology called a microfluidic probe which can interact with tissue sections at the micrometer scale to help unravel some of the molecular variations within tumors.

The collaboration between IBM and the University Hospital Zürich puts a strong emphasis on uncovering the heterogeneity of tumors. More specifically, the collaboration focuses on lung cancer, which is one of the most prevalent forms of cancer and has a high mortality rate.

“Pathologists are determined to obtain as much accurate information as possible from markedly small biopsy samples”, said Prof. Dr. Alex Soltermann, a pathologist specializing in lung cancer at the Institute for Surgical Pathology of the University Hospital Zürich. “We hope to introduce new technologies, such as the microfluidic probe, into the clinical molecular pathology diagnostic framework to enable a range of investigations, which were previously thought to be infeasible. If we are successful, the tool will be a driver for personalized medicine, and translate into increased confidence in diagnosis and better detection of predictive cancer markers.”

Privatdozent Dr. Peter Schraml, director of the tissue biobank at the Institute of Surgical Pathology, University Hospital Zürich, said, “In addition to assisting in diagnostics, this tool may provide insight into the biomarker distribution in tumor tissues, which can aid in understanding cancer progression.”

The eight-millimeter-wide, diamond-shaped probe consists in its simplest form of a silicon microfluidic head ending with a small tip bearing two microchannels.

“For about a year we have been testing the probe in our lab, and initial results are very encouraging – we are now developing the technology in the context of important aspects in pathology” said Dr. Govind Kaigala, a scientist at IBM Research – Zurich. “Over the next several months, we will install a prototype device at the hospital and work alongside pathologists.”

The tool which houses the microfluidic probe was recently made significantly more compact and user-friendly and today is roughly the size of a tissue box – it is now at stage where it may assist in studying the distribution of low numbers of cancer cells in biopsied samples.

How does it work?

The probe injects very small volumes of reagents on the tissue surface and then continuously aspirates the reagents to prevent spreading and accumulation. This approach is used to deliver and retrieve reagents locally in selected areas of a tissue section with pinpoint accuracy. This local interaction with the tissue sample helps in mapping the heterogeneity in the tissue.

“We are very excited to partner with IBM on the microfluidic probe technology to develop techniques for its use in the clinical pathology framework – this is a fine example of a translational research that could also help answer some basic science questions” says Prof. Holger Moch, head of the Institute of Surgical Pathology at the University Hospital Zürich.

IBM scientists aspire to eventually partner with a medical equipment manufacturer to license the technology and bring it to market as a tool to assist pathologists in making challenging and critical decisions. The microfluidic probes are designed and manufactured at the Binnig and Rohrer Nanotechnology Center on the campus of IBM Research - Zurich.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

IBM’s Biomedical Analytics Platform Helps Doctors Personalise Treatment
Italy’s Istituto Nazionale dei Tumori testing new decision support solutions for cancer treatments.
Tuesday, March 20, 2012
New Silicon Probe Assists in Disease Diagnostics and Drug Discovery
Scientists have developed a flexible, non-contact microfluidic probe made from silicon that can aid researchers and pathologists to investigate critical tissue samples accurately, reducing the need for large biopsy samples.
Monday, January 16, 2012
IBM and University Researchers to Develop Research Tools to Improve Cancer Patient Outcomes
Advanced imaging and computer technologies aimed at providing for reliable prognosis leading to more personalized treatment.
Wednesday, February 13, 2008
IBM Joins Forces with top Cancer Centers
IBM Collaborates with MSKCC, the Molecular Profiling Institute and Sainte-Justine Research Center.
Friday, November 11, 2005
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Mystery of Early Embryonic Development Solved
Breakthrough genomics technique can be used to map epigenetic marks across the genome using fewer cells and will benefit cancer research
Using Stem Cells to Grow a 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!